Evelo Biosciences Closes $25.5 Million Private Placement
Restructures and reduces secured debt with Horizon Technology Finance Corporation
Appoints two new members and decreases size of Board of Directors
Related news for (EVLO)
- Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
- Evelo Biosciences Announces $25.5 Million Private Placement